Riskpilot← Back to searchSign inGet full accessStockholms Akutläkargrupp AB
ABActiveOrg 5567508485Grev Turegatan 62 Lgh 1201General medical practice activities · NACE 8621Est. 20080 employees
Revenue 2025
SEK 16,2M
-11% vs 2024
EBITDA margin
22.6%
-13% vs 2024
Equity ratio
56.0%
Financial strength
Net profit 2025
SEK 2,9M
-13% vs 2024
| Revenue | SEK 16,2M | -11% |
| EBITDA | SEK 3,7M | -13% |
| Net profit | SEK 2,9M | -13% |
| Total assets | SEK 5,3M | -3% |
| Equity | SEK 3M | -18% |
| Employees | 0 | — |
Legal name
Stockholms Akutläkargrupp AB
Org number
5567508485
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
29 januari 2008
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska tillhandahålla medicinska tjänster och bedriva därmed förenlig verksamhet.
Address
Grev Turegatan 62 Lgh 1201
Phone
+4687531450
Email
thomas@ehrengren.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 15 694 | 15 547 | 16 982 | 18 266 | 16 227 |
| Staff expenses | — | — | — | −0 | −0 |
| EBITDA | 3 875 | 4 056 | 4 180 | 4 230 | 3 675 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 3 875 | 4 056 | 4 180 | 4 230 | 3 675 |
| Net financials | −3 | — | 5 | −7 | 1 |
| Profit before tax | 3 901 | 4 659 | 4 185 | 4 223 | 3 676 |
| Tax | −826 | −985 | −893 | −906 | −790 |
| Net profit | 3 075 | 3 674 | 3 292 | 3 317 | 2 886 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 756 | 6 299 | 7 743 | 5 477 | 5 340 |
| Equity | 3 270 | 3 944 | 3 537 | 3 653 | 2 990 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 2 882 | 2 355 | 4 206 | 1 824 | 2 351 |
| Total debt | 2 882 | 2 355 | 4 206 | 1 824 | 2 351 |
EBITDA margin
22.6%
This company
15.8%
Market median
+43% vs market
20212025
Equity ratio
56.0%
This company
38.2%
Market median
+47% vs market
20212025
Return on equity
96.5%
This company
18.4%
Market median
+424% vs market
20212025
Net profit margin
17.8%
This company
8.1%
Market median
+120% vs market
20212025
Asset turnover
3.04×
This company
1.12×
Market median
+171% vs market
20212025
Debt / equity
0.79×
This company
0.62×
Market median
+27% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TB Chief Executive Officer | Chief Executive Officer | 2022 |
ZV Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Stockholms Akutläkargrupp AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Börje Ehrengren | Chief Executive Officer | 0 companies |
| Zinovea Vavolidu | Audit | 0 companies |
| Carl Fredrik Gustaf Levin | Chairman | 0 companies |
| Klas Johan Pekkari | Deputy Board Member | 0 companies |